Accessibility Menu

Northwest Biotherapeutics(STG) NBYB

Market Cap€255.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€0.15
+0.00%
+0.00Today

Northwest Biotherapeutics Financials at a Glance

Market Cap

€255.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.86

Net Income (TTM)

-€32.32

EPS (TTM)

-€0.02

P/E Ratio

-6.91

Dividend

€0.00

Beta (Volatility)

0.09 (Low)

Price

€0.15

Volume

3,000

Open

€0.15

Previous Close

€0.15

Daily Range

€0.15 - €0.15

52-Week Range

€0.10 - €0.38

Estimated Earnings Date

N/A

NBYB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.

Industry

Biotechnology

Sector

Health Care

Employees

25

CEO

Linda F. Powers

Website

www.nwbio.com

NBYB Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-14.47%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€255.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.71B

Volume

3.00K

Avg. Volume

21.79K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Northwest Biotherapeutics Performance Analysis

Northwest Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 1,601,37188.3%
20232023-12-31EUR 1,787,04311.6%
20242024-12-31EUR 1,277,629-28.5%
20252025-12-31EUR 1,221,006-4.4%
Northwest Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.1094.5%
20232023-12-31EUR -0.05-45.9%
20242024-12-31EUR -0.0619.2%
20252025-12-31EUR -0.04-41.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€0.69

+6.0%

Gross Profit

-€0.04

+0.1%

Gross Margin

-5.58%

+0.0%

Market Cap

€255.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€9.53

N/A

Employees

25

N/A

Net Income

-€7.93

+0.6%

EBITDA

-€9.25

+0.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€55.71

-11.8%

Total Debt

€55.19

+0.9%

Accounts Receivable

N/A

N/A

Inventory

€0.00

N/A

Long Term Debt

€19.86

+0.8%

Short Term Debt

€35.33

+1.0%

Return on Assets

-70.47%

+0.2%

Return on Invested Capital

127.72%

N/A

Free Cash Flow

-€6.40

+1.2%

Operating Cash Flow

-€6.23

+1.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,717.36+0.00%
^DJIDJI
$53,482.79+0.00%
^IXICNASDAQ
$26,348.25+0.00%
BTCBitcoin
$68,270.00+0.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBSWebster Financial
$77.57-0.01%
IBITiShares Bitcoin Trust
$38.78+0.06%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.74-0.06%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.05+0.06%

Questions About NBYB

What is the current price of Northwest Biotherapeutics?

Northwest Biotherapeutics is trading at €0.15 per share.

What is the 52-week range for Northwest Biotherapeutics?

Over the past 52 weeks, Northwest Biotherapeutics has traded between €0.10 and €0.38.

How much debt does Northwest Biotherapeutics have?

As of the most recent reporting period, Northwest Biotherapeutics reported total debt of €55.19M.

How much cash does Northwest Biotherapeutics have on hand?

Northwest Biotherapeutics reported €520.42K in cash and cash equivalents in its most recent financial results.

What is Northwest Biotherapeutics’s dividend yield?

Northwest Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services